1-3 of 3
sorafenib
Close
Sort by
Journal Articles

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

Blake S. Moses, Samantha McCullough, Jennifer M. Fox, Bryan T. Mott, Søren M. Bentzen, MinJung Kim, Jeffrey W. Tyner, Rena G. Lapidus, Ashkan Emadi, Michelle A. Rudek, Tami J. Kingsbury, Curt I. Civin
Journal: Blood Advances
Blood Adv (2021) 5 (3): 711–724.
https://doi.org/10.1182/bloodadvances.2020003429
Published: 2021
Includes: Supplemental data
Journal Articles

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D. J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David C. Taussig, Spiros Linardopoulos
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1478–1491.
https://doi.org/10.1182/bloodadvances.2019000986
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3 -mutated acute myeloid leukemia: CALGB 11001

Clinical Trials & Observations
Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2017) 1 (5): 331–340.
https://doi.org/10.1182/bloodadvances.2016003053
Published: 2017